UZ Leuven
Leuven, 3000, Belgium
Location status: Recruiting
Location contact
Aline Van der Vorst, MD
CONTACT
Caroline Weltens, MD, PhD
PRINCIPAL_INVESTIGATOR
CONTACT
NCT Number: NCT07373782
This study is a prospective, non-randomized clinical study aimed at investigating the potential benefits of continuous positive airway pressure (CPAP) support during radiotherapy for breast cancer. CPAP is a device commonly used to support breathing, for example in patients with sleep apnea. The investigators expect a reduction in radiation doses to the heart and/or lungs with CPAP-supported radiotherapy compared to standard radiotherapy (without CPAP), which may also lead to a decrease in radiation-induced heart and/or lung conditions in the long term. The study will also examine how the use of a CPAP device can be implemented in daily radiotherapy practice.
Interested in participating?
Request Info40 year–80 year
Female
Interventional
Phase 2 / Phase 3
Leuven, 3000, Belgium
Location status: Recruiting
Aline Van der Vorst, MD
CONTACT
Caroline Weltens, MD, PhD
PRINCIPAL_INVESTIGATOR
CONTACT
Patients undergoing breast conserving surgery for invasive or in situ BC and requiring adjuvant RT are prospectively enrolled -either left-sided cases with or without regional nodal irradiation (RNI), or right-sided cases requiring RNI. Each patient undergoes an additional CT simulation with continuous positive airway pressure (CPAP) (15cm H20) -in free breathing (FB) for right-sided cases and in deep inspiration breath hold (DIBH) for left-sided cases. Left-sided patients unable to perform DIBH are evaluated in FB. Two RT plans (with and without CPAP) are dosimetrically compared. If CPAP reduces mean heart or CLB dose by ≥0.5 Gy, or mean lung dose by ≥1 Gy, treatment is delivered with CPAP. Patient comfort is assessed through surveys.
Healthy volunteers accepted: No
Only the study team can determine whether someone qualifies for participation.
Inclusion criteria
Exclusion criteria
Positive airway pressure (15cmH2O) delivered by a CPAP-device
Time frame: From enrollment to the end of treatment at +/-8 weeks
Potential change of mean radiation dose to the heart
Time frame: From enrollment to the end of treatment at +/-8 weeks
Potential change in radiation dose to cardiac substructures
Time frame: From enrollment to the end of treatment at +/-8 weeks
Potential change in mean radiation dose to the lungs
Time frame: From enrollment to the end of treatment at +/-8 weeks
Potential change in mean radiation dose to the contralateral breast
Time frame: From enrollment to the end of treatment at +/-8 weeks
Potential change in radiation dose to the liver
Time frame: From enrollment to the end of treatment at +/-8 weeks
Patient comfort assessed through patient questionnaires (Likert scale: Strongly disagree - disagree - neutral - agree - strongly agree)
Time frame: From enrollment to the end of treatment at +/-8 weeks
Compare reproducibility and accuracy between standard and CPAP-assisted RT by using surface scanning and daily cone beam CT (CBCT) parameters
Time frame: From enrollment to the end of treatment at +/-8 weeks
To compare DIBH performance between standard and CPAP-assisted RT for left-sided BC by using surface scanning and daily CBCT parameters
Time frame: From enrollment to the end of treatment at +/-8 weeks
To compare time-effectiveness between standard and CPAP-assisted RT
Contact information is provided by the study sponsor or research team.
Universitaire Ziekenhuizen KU Leuven
Other
Reducing Cardiac Radiation Dose in Continuous Positive Airway Pressure (CPAP) Assisted Radiotherapy in Breast Cancer: a Prospective Non-Randomized Clinical Trial
OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.
View the official ClinicalTrials.gov record (opens in a new tab)This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.
Published trials that share one or more normalized conditions with this study.
NCT06970912
Breast Cancer Early Stage Breast Cancer (Stage 1-3), Breast Diseases
Beijing, Beijing Municipality, China
View Trial DetailsNCT06930521
Breast Cancer, Breast Cancer Early Stage Breast Cancer (Stage 1-3)
Toronto, Ontario, Canada
View Trial DetailsNCT07273357
Adjuvant Drug Therapy, Breast Cancer Early Stage Breast Cancer (Stage 1-3)
Gävle, Sweden
View Trial DetailsNCT07387445
Behavior, Breast Cancer
Chicago, Illinois, United States
View Trial Details